RE: What a Mess6 Jun 2019 15:48
End of the day it sounds like a total c0ck up with so called experienced teams. Basics to not have an extended ALT period knowing toxicity levels would be a concern, and clearly stopping at 2 weeks when levels were not at base like again. Surely this is fairly basic phase 3 stuff, you expect them to target a period to allow base lines to return. For all we know this could have swung things.
I also found too much “we don’t know”. How can can you have the dialogue with the FDA then sit on a con call and have no clue what’s going on and how/what/why.
This shows a total lack of leadership imo.
I have now sold out at a 50% loss off the back of the con call, and the utter shambles it seems from the
Motif team and I honestly wonder what else they didn’t do/hidden, so have a feeling a fairly significant trial will be required
I also found it hard to swallow that GL felt no further trials needs, sat at interviews with confidence to find out the news today. That’s either a lack of understanding of the science and his area of supposed expertise or again, not having a clue what’s going on in his own company
Confidence gone in Motif and god knows what they will do with funding now
GL to all staying